3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
2
Sarcoma
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Sarcoma
2
Mesothelioma, Malignant
2
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Neoplasm Metastasis
1
MSI-H Colorectal Cancer
1
Gastro-enteropancreatic neuroendocrine tumor
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Anus Neoplasms
1
Advanced Refractory Solid Tumors
1
Interventions
pembrolizumab
6
Nivolumab
3
tislelizumab
2
budigalimab
2
Ipilimumab
2
Depsipeptides
2
Decitabine
2
venetoclax
1
talazoparib
1
spartalizumab
1
sargramostim
1
rovalpituzumab tesirine
1
regorafenib
1
poly ICLC
1
iodixanol
1
epacadostat
1
entinostat
1
durvalumab
1
cemiplimab
1
avelumab
1
atezolizumab
1
alvocidib
1
Tomography, Optical Coherence
1
Tissue Banks
1
Tablets
1
Radiosurgery
1
Radiofrequency Ablation
1
Paclitaxel
1
Iohexol
1
Interferon-gamma
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
regorafenib
×
Other solid neoplasm
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn